{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:43:22Z","timestamp":1763642602252},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"TRSS limited company"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pancreatology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.pan.2019.04.007","type":"journal-article","created":{"date-parts":[[2019,4,22]],"date-time":"2019-04-22T15:18:34Z","timestamp":1555946314000},"page":"569-577","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Verification of the effectiveness of fucosylated haptoglobin as a pancreatic cancer marker in clinical diagnosis"],"prefix":"10.1016","volume":"19","author":[{"given":"Masaki","family":"Kuwatani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimasa","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumichi","family":"Kawakubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi M.","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Togo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Kusama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teizo","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pan.2019.04.007_bib1","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrclinonc.2015.53","article-title":"Pancreatic cancer: from state-of-the-art treatments to promising novel therapies","volume":"12","author":"Garrido-Laguna","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.pan.2019.04.007_bib2","first-page":"4873089","article-title":"Can molecular biomarkers change the paradigm of pancreatic cancer prognosis?","author":"Martinez-Useros","year":"2016","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.pan.2019.04.007_bib3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.pan.2014.10.001","article-title":"Addressing the challenges of pancreatic cancer: future directions for improving outcomes","volume":"15","author":"Hidalgo","year":"2015","journal-title":"Pancreatology"},{"key":"10.1016\/j.pan.2019.04.007_bib4","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00535-014-1026-z","article-title":"Diagnostic strategies for early pancreatic cancer","volume":"50","author":"Hanada","year":"2015","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.pan.2019.04.007_bib5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.soc.2015.11.004","article-title":"Role of endoscopic ultrasonography and endoscopic retrograde cholangiopancreatography in the clinical assessment of pancreatic neoplasms","volume":"25","author":"Varadarajulu","year":"2016","journal-title":"Surg Oncol Clin"},{"key":"10.1016\/j.pan.2019.04.007_bib6","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.3748\/wjg.v20.i13.3620","article-title":"Influence of the safety and diagnostic accuracy of preoperative endoscopic ultrasound-guided fine-needle aspiration for resectable pancreatic cancer on clinical performance","volume":"20","author":"Kudo","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.pan.2019.04.007_bib7","first-page":"128","volume":"vol. 11","author":"Bussom","year":"2010"},{"key":"10.1016\/j.pan.2019.04.007_bib8","first-page":"11683","article-title":"Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis","volume":"8","author":"Zhang","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.pan.2019.04.007_bib9","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ejso.2006.10.004","article-title":"Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer","volume":"33","author":"Goonetilleke","year":"2007","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.pan.2019.04.007_bib10","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.3748\/wjg.14.3750","article-title":"Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma","volume":"14","author":"Zhang","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.pan.2019.04.007_bib11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00006676-200404000-00009","article-title":"Serum tumor markers and molecular biological diagnosis in pancreatic cancer","volume":"28","author":"Sawabu","year":"2004","journal-title":"Pancreas"},{"key":"10.1016\/j.pan.2019.04.007_bib12","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.3748\/wjg.v21.i14.4323","article-title":"Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis","volume":"21","author":"Su","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.pan.2019.04.007_bib13","doi-asserted-by":"crossref","first-page":"6569","DOI":"10.7314\/APJCP.2015.16.15.6569","article-title":"Applicative value of serum CA19-9, CEA, CA125 and CA242 in diagnosis and prognosis for patients with pancreatic cancer treated by concurrent chemoradiotherapy","volume":"16","author":"Gu","year":"2015","journal-title":"Asian Pac J Cancer Prev APJCP"},{"key":"10.1016\/j.pan.2019.04.007_bib14","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/jb\/mvn011","article-title":"Biological function of fucosylation in cancer biology","volume":"143","author":"Miyoshi","year":"2008","journal-title":"J\u00a0Biochem"},{"key":"10.1016\/j.pan.2019.04.007_bib15","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1002\/ijc.21728","article-title":"Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation","volume":"118","author":"Okuyama","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.pan.2019.04.007_bib16","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1002\/ijc.23364","article-title":"Site-specific analysis of N-glycans on haptoglobin in sera of patients with pancreatic cancer: a novel approach for the development of tumor markers","volume":"122","author":"Nakano","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.pan.2019.04.007_bib17","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1002\/pmic.200800046","article-title":"Fucosylated haptoglobin is a novel marker for pancreatic cancer: detailed analyses of oligosaccharide structures","volume":"8","author":"Miyoshi","year":"2008","journal-title":"Proteomics"},{"key":"10.1016\/j.pan.2019.04.007_bib18","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1016\/S0021-9258(18)89125-6","article-title":"Fractionation of L-fucose-containing oligosaccharides on immobilized Aleuria aurantia lectin","volume":"260","author":"Yamashita","year":"1985","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.pan.2019.04.007_bib19","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1515\/CCLM.2010.095","article-title":"Clinical application of a lectin-antibody ELISA to measure fucosylated haptoglobin in sera of patients with pancreatic cancer","volume":"48","author":"Matsumoto","year":"2010","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.pan.2019.04.007_bib20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cca.2012.12.014","article-title":"Reevaluation of a lectin antibody ELISA kit for measuring fucosylated haptoglobin in various conditions","volume":"417","author":"Kamada","year":"2013","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.pan.2019.04.007_bib21","doi-asserted-by":"crossref","first-page":"33973","DOI":"10.1074\/jbc.M111.327692","article-title":"A\u00a0novel core fucose-specific lectin from the mushroom Pholiota squarrosa","volume":"287","author":"Kobayashi","year":"2012","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.pan.2019.04.007_bib22","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.pan.2016.01.004","article-title":"Specific increase in serum core-fucosylated haptoglobin in patients with chronic pancreatitis","volume":"16","author":"Ueda","year":"2016","journal-title":"Pancreatology"},{"key":"10.1016\/j.pan.2019.04.007_bib23","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s10719-017-9772-9","article-title":"Reevaluation of Pholiota squarrosa lectin-reactive haptoglobin as a pancreatic cancer biomarker using an improved ELISA system","volume":"34","author":"Kusama","year":"2017","journal-title":"Glycoconj J"},{"key":"10.1016\/j.pan.2019.04.007_bib24","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"key":"10.1016\/j.pan.2019.04.007_bib25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10552-017-0991-y","article-title":"Serum lipids and risk of obesity-related cancers in postmenopausal women","volume":"29","author":"Kabat","year":"2018","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.pan.2019.04.007_bib26","doi-asserted-by":"crossref","first-page":"382","DOI":"10.5858\/133.3.382","article-title":"Chronic pancreatitis and the differential diagnosis versus pancreatic cancer","volume":"133","author":"Kl\u00f6ppel","year":"2009","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.pan.2019.04.007_bib27","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1148\/rg.256055036","article-title":"Intraductal papillary mucinous neoplasm of the pancreas: can benign lesions be differentiated from malignant lesions with multidetector CT?","volume":"25","author":"Kawamoto","year":"2005","journal-title":"Radiographics"},{"key":"10.1016\/j.pan.2019.04.007_bib28","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1074\/mcp.M112.023259","article-title":"Site-specific glycoforms of haptoglobin in liver cirrhosis and hepatocellular carcinoma","volume":"12","author":"Pompach","year":"2013","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.pan.2019.04.007_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066328","article-title":"Serum fucosylated haptoglobin as a novel\u00a0diagnostic biomarker for predicting hepatocyte ballooning and nonalcoholic steatohepatitis","author":"Kamada","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pan.2019.04.007_bib30","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1002\/cncr.26490","article-title":"Fucosylated haptoglobin is a novel type of cancer biomarker linked to the prognosis after an operation in colorectal cancer","volume":"118","author":"Takeda","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.pan.2019.04.007_bib31","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/pros.22824","article-title":"Serum fucosylated haptoglobin as a novel prognostic biomarker predicting high-Gleason prostate cancer","volume":"74","author":"Fujita","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.pan.2019.04.007_bib32","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cca.2015.03.037","article-title":"Establishment of a novel lectin-antibody ELISA system to determine core-fucosylated haptoglobin","volume":"446","author":"Shimomura","year":"2015","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.pan.2019.04.007_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046908","article-title":"Altered plasma apolipoprotein modifications in patients with pancreatic cancer: protein characterization and multi-institutional validation","author":"Honda","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.pan.2019.04.007_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/srep15921","article-title":"Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms","author":"Honda","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.pan.2019.04.007_bib35","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.2217\/bmm-2016-0209","article-title":"Potential usefulness of apolipoprotein A2 isoforms for screening and risk stratification of pancreatic cancer","volume":"10","author":"Honda","year":"2016","journal-title":"Biomark Med"},{"key":"10.1016\/j.pan.2019.04.007_bib36","first-page":"4671","article-title":"Can Serum ICAM 1 distinguish pancreatic cancer from chronic pancreatitis?","volume":"17","author":"Mohamed","year":"2016","journal-title":"Asian Pac J Cancer Prev APJCP"},{"key":"10.1016\/j.pan.2019.04.007_bib37","doi-asserted-by":"crossref","first-page":"77854","DOI":"10.18632\/oncotarget.12835","article-title":"Serum APN\/CD13 as a novel diagnostic and prognostic biomarker of pancreatic cancer","volume":"7","author":"Pang","year":"2016","journal-title":"Oncotarget"}],"container-title":["Pancreatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S142439031930095X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S142439031930095X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T14:13:17Z","timestamp":1663337597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S142439031930095X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S142439031930095X"],"URL":"https:\/\/doi.org\/10.1016\/j.pan.2019.04.007","relation":{},"ISSN":["1424-3903"],"issn-type":[{"value":"1424-3903","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Verification of the effectiveness of fucosylated haptoglobin as a pancreatic cancer marker in clinical diagnosis","name":"articletitle","label":"Article Title"},{"value":"Pancreatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pan.2019.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V. on behalf of IAP and EPC.","name":"copyright","label":"Copyright"}]}}